Related Experiment Video
Updated: Jun 14, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review
Min Tang1,2, Yijun Wu1,2, Xiufeng Bai3,4
1Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Abstract:
Rat sarcoma virus (RAS) GTPase is one of the most important drivers of non-small cell lung cancer (NSCLC). RAS has three different isoforms (Harvey rat sarcoma viral oncogene homolog [HRAS], Kirsten rat sarcoma viral oncogene homolog [KRAS] and Neuroblastoma ras viral oncogene homolog [NRAS]), of which KRAS is most commonly mutated in NSCLC. The mutated KRAS protein was historically thought to be "undruggable" until the development of KRASG12C inhibitors. In this review, from the aspect of brain metastasis, we aim to provide an overview of the advances in therapies that target KRASG12C, the limitations of the current treatments, and future prospects in patients with KRAS p.G12C mutant NSCLC.
Insights
Targeting KRAS G12C mutations in non-small cell lung cancer (NSCLC) shows promise, especially for brain metastases. This review covers current KRAS G12C therapies, their limitations, and future directions for NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Rat sarcoma virus (RAS) GTPase mutations are key drivers in non-small cell lung cancer (NSCLC).
- Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most frequently mutated RAS isoform in NSCLC.
- KRAS mutations, particularly G12C, were historically considered undruggable targets.
Purpose of the Study:
- To review advances in therapies targeting KRAS G12C mutations in NSCLC.
- To discuss the challenges and limitations of current KRAS G12C inhibitor treatments.
- To explore future prospects for managing brain metastases in KRAS p.G12C mutant NSCLC patients.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of therapeutic strategies targeting KRAS G12C.
- Focus on outcomes related to brain metastasis in NSCLC.
Main Results:
- Development of specific KRAS G12C inhibitors has emerged as a breakthrough therapy.
- Current therapies show efficacy but face limitations in overcoming resistance and treating specific complications like brain metastases.
- Further research is needed to optimize treatment strategies and improve patient outcomes.
Conclusions:
- KRAS G12C inhibitors represent a significant advancement in NSCLC treatment.
- Addressing treatment limitations, especially for brain metastases, is crucial for improving survival.
- Future research should focus on novel therapeutic approaches and combination strategies for KRAS-mutant NSCLC.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...